Biocon Ltd News Today

In its filing with the bourses, the company reported that the current contract period of 36 months has been extended for an additional six months.

As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.

The operating performance was also good as EBITDA increased 17.7% to ₹1,078.2 crore in March quarter compared with ₹915.9 crore in Q4 FY24.

Yesintek has been added to Express Scripts' National Preferred Formulary (NPF), effective March 21, 2025.

The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.

Here are some of the stocks that may see significant price movement today: LTIMindtree, Dalmia Bharat, Bajaj Housing, etc.

Jobevne is a vascular endothelial growth factor (VEGF) impediment that sticks with VEGF and restrain the interaction with its receptors.

The first approval is for the 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths of Lenalidomide Capsules.

Civica will start selling the medicine for patients in the United States after completing development work and clinical trials.

The drug is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults who have shown resistance or intolerance to prior therapy.